Hepatocellular carcinoma (HCC) is a highly heterogeneous malignant tumor with significant differences in invasion, proliferation ability and patient prognosis. Currently, there is a lack of non-invasive and simple indicators to predict the prognosis of HCC patients and assist clinical decision-making. The identification of HCC macroscopic or histopathological classification requires large pathological specimens obtained through surgical resection, but only about 20% of patients are eligible for surgical treatment. Moreover, most liver cancer diagnoses can be confirmed by imaging examinations without relying on pathological results. For patients who have not undergone surgical resection, the lack of histopathological information during treatment means that there is no basis for judging tumor proliferation and obtaining rich prognostic information. Therefore, evaluating the invasion and proliferation ability of HCC based on macroscopic imaging assessment has important implications for guiding individualized diagnosis and treatment throughout the entire process including surgical strategy guidance, local treatment selection, systemic therapy planning as well as patient follow-up and prognosis evaluation. Ultrasound and MRI are ideal entry points as first-line imaging methods for liver cancer diagnosis. This study aims to evaluate HCC macroscopic or histopathological classification based on multimodal imaging (ultrasound, CT, MRI), thereby assessing its invasion and proliferation ability which has important implications for guiding individualized diagnosis and treatment throughout the entire process including surgical strategy guidance, local treatment selection, systemic therapy planning as well as patient follow-up and prognosis evaluation. By analyzing macroscopic image features we aim to explore their cross-scale correlations with HCC macroscopic classification,histopathological classification,and gene molecular typing.
Study Type
OBSERVATIONAL
Enrollment
500
According to guideline recommended procedure of hepatectomy
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
RECRUITINGOverall survival
OS was defined as death related to any cause and was indexed from the date of ablation or surgery until last contact or death
Time frame: through study completion, an average of 1 year
Disease-free survival
DFS was defined as the time interval between first treatment and recurrence or death, whichever occurred earlier
Time frame: through study completion, an average of 1 year
Imaging features
MRI or ultrasound Imaging features of the four types
Time frame: through study completion, an average of 1 year
Quantification of immune cells of the resected liver tumour
Quantification of immune cells of the resected liver tumour using HE staining and immunohistological staining to assess molecular marker and cell infiltration in tumor and liver parenchyma
Time frame: through study completion, an average of 1 year
mRNA sequencing data of the resected liver tumour and peritumor parenchyma
mRNA sequencing data of the resected liver tumour and peritumor parenchyma specimen to assess the gene enrichment
Time frame: through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.